News & Analysis on Contract Research, Manufacturing & Clinical Trials
DCAT WEEK '17
CMC Biologics: Business as usual
By Melissa Fassbender
- Last updated on
Robert Broeze, PhD, Chief Business Officer, said CMC Biologics has steadily grown 20% in the last few years and the company is forecasted to grow at the same rate over the next three years.
Broeze also said the company with further add to its capabilities in order to meet a growing commercial demand, in addition to extending its reach further in Europe and establishing a footprint in Asia, he said.
The company also expects additional growth through future acquisitions and investment as AGC – which acquired CMC in December 2016 – has “a very aggressive acquisition plan.”
“AGC is executing on its strategic plan to become larger presence in the life sciences industry,” said Broeze. “Our future is business as usual,” he added. “We plan to continue to grow the business.”